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Abstract
Background: Plasma metabolomics profile (PMP) in COPD has been associated with clinical characteristics, but
PMP’s relationship to survival has not been reported. We determined PMP differences between patients with COPD
who died an average of 2 years after enrollment (Non-survivors, NS) compared to those who survived (S) and also
with age matched controls (C).
Methods: We studied prospectively 90 patients with severe COPD and 30 controls. NS were divided in discovery
and validation cohorts (30 patients each) and the results compared to the PMP of 30 S and C. All participants
completed lung function tests, dyspnea scores, quality of life, exercise capacity, BODE index, and plasma metabolomics
by liquid and gas chromatography / mass spectometry (LC/MS, LC/MS2, GC/MS). Statistically, we used Random Forest
Analysis (RFA) and Support Vector Machine (SVM) to determine metabolites that differentiated the 3 groups and
compared the ability of metabolites vs. clinical characteristics to classify patients into survivors and non-survivors.
Results: There were 79 metabolites statistically different between S and NS [p < 0.05 and false discovery rate (q value)
< 0.1]. RFA and SVM classification of COPD survivors and non-survivors had a predicted accuracy of 74 and 85%
respectively. Elevation of tricyclic acid cycle intermediates branched amino acids depletion and increase in lactate,
fructose and xylonate showed the most relevant differences between S vs. NS suggesting alteration in mitochondrial
oxidative energy generation. PMP had similar predictive power for risk of death as information provided by clinical
characteristics.
Conclusions: A plasma metabolomic profile characterized by an oxidative energy production difference between
survivors and non-survivors was observed in COPD patients 2 years before death.
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Background
Chronic obstructive pulmonary disease (COPD) is a
significant cause of morbidity and mortality around the
world [1] .The disease is diagnosed by the presence of
persistent airflow limitation in subjects with exposure to
the appropriate risk (cigarette smoking and/or exposure
to environmental pollution) [2] .It has several systemic
repercussions and is associated to comorbidities that im-
pact on survival [3]. The severity of airflow limitation
and dypsnea and the presence of low body mass index
and decrease exercise capacity are known clinical factors
able to predict risk of death, especially when integrated
into the multidimensional BODE index [4].
Metabolomic profiling refers to the systematic analysis
of low molecular weight biochemicals, including sugars,
amino acids (AA’s), organic acids, nucleotides and lipids
in a biological specimen [5]. In COPD patients, several
platforms and matrices have been studied including
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exhaled gas condensate, urine and plasma [6, 7]. More
recently, a plasma metabolic profiling (PMP) has shown
association of several amino acids with cachexia and em-
physema, as reported in the ECLIPSE cohort [8]. A subse-
quent study described the relation between 34 targeted
amino acids and dipeptides in different subgroups of
COPD patients (emphysema, airway disease or cachexia)
[9]. In patients from the COPDGene cohort, Bowler and
coworkers observed relations between sphingomyelin and
ceramides with airflow obstruction and emphysema [10].
We hypothesized that patients with severe COPD at risk
of dying have metabolomic alterations that differentiate
them from survivors and that the discriminative power of
the metabolites would be similar to that provided by the
clinical information provided by the BODE index and its
variables. To test this hypothesis, we performed an untar-
geted metabolomic profiling of COPD patients and age
matched controls, that included not only amino acids, but
also peptides, carbohydrates, components of the Krebs
cycle, oxidative phosphorylation, and several lipids (essen-
tial, medium and long chain fatty acids, lyso and sphingoli-
pids) to describe a more global metabolic disarrangement
that could differentiate survivors from non-survivors.
Materials and methods
Clinical data
We prospectively recruited and followed for over 3 years a
group of 90 COPD patients and 30 age-gender matched
controls (C). The 60 COPD patients that died during the
study (non-survivor or NS) were equally divided in 2
groups: discovery (NSd) and validation (NSv). The NSd
group was compared to the survivor (S) COPD group (n =
30) and a control group (n = 30 volunteers with no lung
disease, 40% current smokers and 60% non- smokers). Re-
sults from the 30 NSv were used to validate the findings of
this analysis (Fig. 1 in the supplement). The mean (SD)
survival time for NS was 24 + 19months. All patients were
recruited in Boston and Tenerife (NSv only) following the
same protocol approved by the IRB at both institu-
tions. Lung function, 6 min walk test (6MWT),
dyspnea level (modified Medical Research Council,
mMRC scale), the Saint George Respiratory Question-
naire (SGRQ) and the BODE index [4] were measured
at baseline. Blood was drawn early morning under
fasting condition.
Plasma metabolomic analysis
Plasma metabolomic profile was determined by 2 plat-
forms (version 3 and 4 as described in Fig. 1), using Li-
quid Chromatography/ Mass Spectometry (LC/MS, LC/
MS2) and Gas Chromatography/ Mass Spectrometry
(GC/MS). Both analyses were completed at Metabolon,
Inc. (Durham, NC) (details on the supplemental material
(SM) files). Metabolites identified in 80% of both plat-
forms were included in the final analysis, resulting in the
inclusion of 266 metabolites.
Fig. 1 Flow diagram describes the discovery and validation cohorts, data processing and number of metabolites determined on each experiment
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Statistical methods
We performed a t test and analysis of variance (ANOVA)
with Bonferroni correction for multiple comparisons for
the clinical data among groups.
We used log transformation and imputation with
minimum observed values for each metabolite. Then, we
analyzed the data using 3 complementary methods. First,
Welch’s two-sample t-test to identify biochemicals that
differed significantly between the COPD groups (NSd
and S) and control population (C). A list of metabolites
that differentiate each group was generated. The false
discovery rate (FDR) q value was used to correct for
multiple comparisons.
Second, for group classification, we completed two dif-
ferent analyses; Random Forest (RF) and Support Vector
Machine (SVM) [11] They both estimate how well we can
classify individuals in a new data set into each group. Ran-
dom Forest generates a set of classification trees based on
continual sampling of the experimental units and com-
pounds. Then each observation is classified based on the
majority votes from all the classification trees [12]. The
SVM identifies a linear, maximal-margin decision bound-
ary between the sample groups by solving a quadratic
optimization problem [13]. We used both methods to
increase the validity of the group classification results.
Third, we used a two-sample t-test, linear discriminate
analysis (LDA) and SVM-RFE (a recursive feature elim-
ination or SVM-RFE) to determine how well clinical
characteristics and metabolites classify patients into 3
different groups (COPD survivors, non-survivors and
controls). (See SM). Finally, we used the list of metabo-
lites that separated survivors versus non-survivors dis-
covery to predict and validate the comparison of NSv
group vs. S and to perform a pathways analysis using
MetaboAnalyst software [14].
Results
The clinical characteristics of each group are included in
Table 1. The subjects in the four groups were similar in
age, gender, body mass index, comorbidities and smok-
ing history. As expected, COPD survivors had better
lung function, exercise capacity, quality of life, gas ex-
change and lower BODE index than non-survivors, while
controls had normal lung function, with no difference
between smokers and non-smokers.
Metabolites identification
The 2 platforms measured a total of 395 and 767 com-
pounds of known identity (Fig. 1). Two hundred and
sixty-six metabolites were identified and included in the
final analysis.
First, we compared 3 groups (NSd, S and C) and gen-
erated a list of metabolites that had achieved statistical
significance (p ≤ 0.05) among these 3 groups. Results are
shown in the SM (Additional file 1: Table S1-S3). Table 2
shows the number of metabolites that were statistically
different (t test) in the above-mentioned analysis. There
were 108, 79 and 27 significantly altered biochemicals
Table 1 Clinical characteristics of COPD patients and control population
Variables COPD (NS d) COPD (NS v) COPD (S) Controls p value
N 30 30 30 30
Age (y) 67 ± 10 71 ± 8 68 ± 7 68 ± 7 0.72
Male, % 68 70 59 67 0.73
BMI (kg/m2) 25.8 ± 5 26.7 ± 5 27.3 ± 4 28.8 ± 5 0.05
Smoking (p/y) 68 ± 36 65 ± 6 60 ± 38 58 ± 30 0.5
FVC, % 71 ± 26 70 ± 18 79 ± 14 104 ± 16 < 0.001
FEV1, % 35 ± 12 46 ± 20 45 ± 15 99 ± 17 < 0.001
FRC, % 181 ± 48 153 ± 46 155 ± 47 97 ± 24 < 0.001
DLCO, % 44 ± 14 56 ± 23 64 ± 22 91 ± 24 < 0.001
IC/TLC 0.22 ± 0.06 0.27 ± 0.08 0.33 ± 0.12 0.47 ± 0.09 < 0.001
mMRC 2.7 ± 0.6 1.7 ± 1.4 1.5 ± 1.1 0.13 ± 0.3 < 0.001
6MWT(m) 301 ± 92 408 ± 77 442 ± 125 543 ± 113 < 0.001
BODE 5.3 ± 1.6 3.1 ± 2.2 3 ± 1.9 N/A < 0.001
GOLD 2,3,4, % 6,52,42 40,37,23 34,52,14 N/A < 0.001
SGRQ 56 ± 15 50 ± 12 42 ± 25 11 ± 13 < 0.001
Charlson CI 0.8 ± 1.2 0.6 ± 1.2 0.5 ± 1.1 0.3 ± 0.7 0.30
PaO2 (mmHg) 65 ± 14 58 ± 10 76 ± 11 N/A < 0.002
PaCO2 (mmHg) 46 ± 9 45 ± 6 40 ± 3 N/A < 0.002
NS d Non-survivor discovery. NS v Non-survivor validation S Survivors. Charlson CI Charlson Comorbidity Index. N/A Non-applicable
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(p ≤ 0.05) between NS vs. C, NS vs. S and S vs. C, sug-
gesting a larger metabolic disarrangement as the patients
were clinically more compromised.
There were pronounced elevations in the Tricarboxylic
Acid (TCA) cycle intermediates alpha-ketoglutarate, suc-
cinate/succinylcarnitine, succinate, fumarate, and malate
in COPD non-survivor discovery. Reductions in circulat-
ing levels of the branched-chain amino acids (BCAAs)
leucine, isoleucine, and valine were noted in COPD non-
survivors, along with increased lactate, fructose, and
five-carbon sugars alcohols such as xylonate that are
produced through the pentose phosphate pathway
(PPP). Figure 2 shows a cell diagram of the metabolomic
alterations, most of which are found within the mito-
chondria. Similar findings were observed in the non-
survivors in the validating group (NSd).
Group classification by metabolites
The RF and SVM analyses were used to assess the
separability of the sample into groups and rank
metabolites that are significantly different between
groups. (Table 3). The RF and SVM suggested a
better discrimination between the NSd and C since
the misclassification rate was the lowest for this 2-
groups comparison. The ranking classification of the
metabolites in each group was similar irrespective of
the statistical method used, supporting the validity of
the results.
Group classification using metabolites vs. clinical results
The capacity of the metabolites to classify patients in dif-
ferent groups compared to the combination of clinical
data (BODE index)) is shown in Table 4. This analysis
demonstrated that a smaller group of metabolites (26, 12
and19) could differentiate and classify patients in each
group with excellent accuracy (0.73–0.78) (Additional
file 1: Table S4). The 26 metabolites classified patients in
the 2 COPD groups (Survivors and non-survivors) with
remarkable similarity to the clinical data. We performed
a pathway analysis [14] with these 26 metabolites that
confirmed metabolic pathway alterations in TCA cycle
but also in glyoxylate and dicarboxylate and glycerolipid
metabolism (Fig. 3).
Survival prediction
After elimination of xenobiotics from the initial list
of 266 metabolites, 244 biochemicals were used to
determine a final list of biochemicals that related to
survival. The metabolite list generated during discov-
ery (NSd vs. S) was compared for validation to NSv
vs. S. We used SVM and t test analysis to rank by
weight metabolites that predicted survival. Four me-
tabolites: fructose, hexadecadenionate, hwesasxx (a
fibrinogen split product) and oxalate predicted sur-
vival with 85% accuracy, 81% sensitivity and 89%
sensitivity (Fig. 1).
Discussion
This study reports three novel findings. First, there are
differences in plasma metabolomics profile between
COPD patients who die over a period of 3 years and
those that do not. Secondly, the differences in metabolite
between groups allowed the correct classification of pa-
tients based on their metabolomic signature alone. This
signature validated in a different cohort was as good as
several clinical parameters combined in differentiating
survivors from non survivors. Lastly, metabolic pathways
in COPD survivors and non-survivors identified several
disruptions, particularly in energy metabolism, suggest-
ing that mitochondrial dysfunction plays an important
role in the non-survival group.
Previous studies have reported association of metabolic
signature of patients with COPD [8, 10, 16–18], with clin-
ical characteristics and outcomes including degree of air-
way obstruction and severity of emphysema, exacerbation
and hospitalization but only one has evaluated survival dif-
ferences [19]. However, in that study the analysis was lim-
ited to adrenal hormone metabolites. Different biologic
matrices (plasma, urine and exhaled condensates) [20, 21]
and data sets of functional genomics, proteomics and meta-
bolomics have also been published revealing the complexity
of true “integrated omics [22] Previous work by Ubhi and
colleagues, found differences between COPD patients and
control subjects, and COPD patients characteristics (dis-
ease severity and phenotypes) [8]. The authors specifically
validated amino acids and dipeptides and correlated them
to cachexia, emphysema and GOLD 4 category [9]. A more
recent study by Bowler and colleagues [10] described the
association between plasma sphingolipids and sub-
phenotypes of COPD in over 250 patients from the COPD-
Gene cohort. Five sphingomyelins were associated with
emphysema and 7 ceramides with COPD exacerbation.
This group also described a 15 sphingolipids gene/metabol-
ite pairs differentially regulated between COPD and control
subjects. Despite differences in study design, number of
subjects, and quantification methods, our findings were
similar to the ones reported in these 2 cohorts, including a
Table 2 Comparison between the 3 different groups.
Biochemicals in red are elevated and in green are reduced
Altered biochemicals NSd vs. C NSd vs. S S vs. C
Total Biochemicals (p < 0.05) 108 79 27
Biochemicals 68/40 54/25 7/20
Total Biochemical(0.05 > p < 0.1) 21 9 19
Biochemicals 14/7 6/3 11/8
Number of elevated ( ) or reduced ( ) metabolites in the group comparison
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reduction in 3 amino acids (branched-chain) and increase
in 2 sphingomyelins (palmitoyl and stearoyl sphingomyelin)
in COPD compared to control subjects.
Our study expands the current knowledge by reporting
a larger number of metabolites albeit in a smaller num-
ber of subjects than previously reported and relating the
difference to risk of death (Table 2). We confirm large
metabolic differences between COPD patients and
controls but also between COPD patients who died ver-
sus those that survived over 3 years of observation. This
differences between patients with different disease sever-
ity is consistent with the findings by Ubhi et al. who
showed significant differences in metabolomic profile
between patients with GOLD stages III and IV vs. con-
trols without COPD, but not between GOLD II patients
and controls [8]. This observation further supports the
notion that the metabolite signature can classify patients
in 3 different groups. As shown in Table 3, we used 2
different supervised learning algorithms to assess the
predictive power of the metabolites to classify subjects
according to 3 different groups. A better classification
capacity was noted by the 2 methods when differentiat-
ing COPD non-survivors vs. controls compared to the
other sets of classification (NSd vs. S and S vs. C).
Nevertheless, the similarity of the results using both
methods supports the validity of the observations.
To further study the ability of the metabolomic ana-
lysis as a classification tool, we compared the
Table 3 Results of 2 different group classification strategies
(SVM and RFA) using statistically significant metabolites (p <
0.05). All values reported as misclassification rates (lower is
better). A rate of approximately 0.5 is equal to chance alone.






NSd. vs. S 0.33 0.30
NSd vs. C 0.18 0.14
S vs. C 0.37 0.37
Fig. 2 Cell diagram depicting metabolomic differences between COPD non-survivors (NS) and COPD survivors (S). The black circles denote
altered metabolic pathways. The majority of these pathways were related to mitochondrial function
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appropriateness of patient allocation into the 3 groups
by metabolic data and a comprehensive panel of clinical
parameters. The clinical parameters selected included
several with demonstrated capacity to predict survival,
either individually (FEV1, dyspnea level, distance walked,
BMI, lung volumes, Pa CO2) or the combination of them
(BODE index). The classification for the COPD patients
(survivors and non-survivors) was quite similar using
both strategies (Table 4). This approach could be
particularly useful since patients in the survivor and
non-survivor groups had severe disease and predicting
survival for any clinician is difficult. Even though we val-
idated the results in a subsequent group of patients with
COPD, further validation in other cohorts is needed to
solidify for the possible use of metabolomic signatures as
prognostic tools in “personalized” medicine.
Metabolomic pathways in COPD survivors and non-
survivors
Figures 2 and 3 and Additional file 1: Table S5 show dif-
ferences in metabolomic pathways comparing COPD
survivors vs. non-survivors. Significant alterations were
observed in the in the TCA cycle with accumulation of
several intermediaries (alpha-ketoglutarate, succinate, fu-
marate, malate), in biochemicals related to glucose metab-
olism including elevation in lactate, glycerate, fructose, in
the pentose phosphate pathway with accumulation of five
sugar carbon alcohol xylonate and other sugar alcohols
threitol, arabitol and fucose and the glyoxylate and dicar-
boxylate metabolism as well as the glycerolipid pathway.
These abnormalities in association with a reduction in
levels of branched-chain amino acids valine, leucine, iso-
leucine, while not confirmed in the validation group, sug-
gests an altered state of oxidative stress. Green et al. [23]
has suggested the existence of “metabolic check points”
that determine cell death; including acetyl CoA produc-
tion abnormalities involving TCA and pentose phosphate
pathway as well as an increase in the production of sphyn-
golipids. Our results in peripheral blood, could represent a
reflection of these alterations in cells throughout the body.
Besides energy metabolism, we found an increase in cir-
culating levels of polypeptides associated to fibrinogen
cleavage in the non-survivor group compared to the
survivors (confirmed in the validation group) and the
biologically-active bradykinin metabolite bradykinin, des-
arg-9. Bradykinin is associated to activation of Factor Xll
and fibrinogen has been associated to increased risk of ex-
acerbation and all-cause mortality in COPD [24, 25].
To our knowledge, this is the first study in COPD pa-
tients where a metabolomic signature based on a wide
range of metabolites has been associated with mortality.
However, metabolomic analysis have been used to pre-
dict clinical outcome in other conditions, including sep-
sis [26, 27], recurrent breast cancer [28] and heart
failure post intervention [29].
This manuscript has several limitations. First, a rela-
tively small number of subjects were enrolled in this
study, particularly when comparing to previous work by
Ubhi et al. [8] and Bowler and coworkers [10]. A recent
article on biomarker discovery suggested a large sample
size (> 500 patients) and reproducibility in at least one
external cohort [30]. To overcome this limitation, we in-
cluded a confirmatory validating cohort and performed
several independent statistical analyses completed by re-
searchers blinded to each other. Indeed, the classification
according to groups (COPD survivors, non-survivors
and control) was tested using 2 different statistical ana-
lysis (SVM and RFA), both showing similar results.
Table 4 Results of the sensitivity, specificity and accuracy analysis to determine the capacity of the list of metabolites (1st digit) and
clinical data (2nd digit) to classify patients in each group. NSd: COPD non-survivor discovery. S: COPD survivor. C: Control
Group Comparison Sensitivity Specificity Accuracy
Metabolites Clinical Metabolites Clinical Metabolites Clinical
NSd vs. S 0.79 0.73 0.77 0.81 0.78 0.78
NSd vs. C 0.8 1 0.77 1 0.79 1
S vs. C 0.8 0.96 0.66 0.89 0.73 0.93
Fig. 3 Metabolome overview depicting matched pathways
according to p values from the pathway enrichment analysis (vertical
axis) and the pathway impact values from the pathway topology
analysis (horizontal axis) [15]. The most significant and over-
represented pathways are related to energy metabolism
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Importantly, we also tested its classification strength
against a group of comprehensive clinical parameters
and found metabolites to be as good as the panel of clin-
ical characteristic with accuracy over 0.7 (Table 4), a
performance benchmark suggested to move biomarker
panels into replication and validation phases [30]. We
implemented this to strengthen the validity and address
the issue of a number of covariates (metabolites) larger
than the number of samples (patients) or “p > n prob-
lem”. In addition, we used the most widely accepted
methods to classify metabolomic data, Random Forest
Analysis and Support Vector Machine [11]. Strong sup-
port to our findings is provided by the fact that several
metabolites in our study were common to previous stud-
ies despite differences in patient selection criteria, study
design and analysis platform. Second: Two different plat-
forms with different capacity to identify metabolites
were used. The confirmatory cohort samples were ana-
lyzed using the second a platform (Fig. 1) which may
have explained why certain findings (branched-chain
amino acids) were not confirmed in the validation cohort.
We restricted the selection of metabolites to those identi-
fied in 80% of the samples from both platforms, limiting
the number of metabolites identified but increasing the
validity of the results. This may have also reduced the
number of common metabolites found on the verification
cohort to only 4. A third limitation is inherent to metabo-
lomic studies in general and refer to the lack of a clear or
unique metabolic signature for each disease and lack of
power analysis and sample size estimation. The relatively
small sample size may have limited the number of metab-
olites and pathways alterations associated to increased
mortality. However, the different and complementary stat-
istical analysis showing significant differences in several
metabolites and pathways provide support to our findings.
That the clinical data and metabolomic results have a
similar prediction for survival is encouraging. In addition,
pathways shown in KEGG charts capture about 90% of
the chemical mass but only show about 60% of the total
number of pathways. However, given that this field is in
constant evolution, we believe that our findings will help
stimulate more research in this area.
A potential fourth limitation is the composition of the
control group, including both smokers and non-
smokers. Although the study was designed to determine
differences in survival in the COPD group, the lung
function was normal and similar between the smokers
and non-smokers and the smoking history in the former
was similar to that of COPD patients thereby minimizing
the role of smoking on the findings.
Conclusion
We have shown that plasma metabolomic profile differs be-
tween COPD patients and controls, with more divergence
as the disease is more severe. The findings offer evidence
that several pathways are involved including energy metab-
olism, probably associated to oxygen transport and mito-
chondrial dysfunction, and the coagulation cascade. The
metabolic signature closely matches the ability of clinical
characteristics to classify patients with COPD as survivors
and non -survivors. On average, samples were drawn 2
years prior to patient’s death, suggesting that plasma meta-
bolomics could have a place in the clinical management of
patients with severe disease and may help not only to pre-
dict outcome but maybe useful as a tool for intervention
and as markers of response to treatment.
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